The effect of glucagon-like peptide-1 receptor agonist therapy on body mass index in adolescents with severe obesity: A randomized, placebo-controlled, clinical trial. JAMA Pediatr 2013; 167: 355-360.Kelly AS, Rudser KD, Nathan BM, et al. The effect of glucagon-like peptide-1 receptor ...
M. (1959) The effect of glucagon and glucose on the human stomach. Amer. J. dig. Dis. 4: pp. 775-786Solomon SP, Spiro HM: The effects of glucagon and glucose on the human stomach. Am J Dig Dis 4:775–786, 1959Solomon, S. P., Spiro, H. M. : The effect of glucagon and ...
The Effect of Glucagon, Phenmetrazine and Epinephrine on Hunger, Food Intake and Plasma Nonesterified Fatty Acids Four healthy young men were the subjects of numerous experiments in which a placebo, glucagon, phenmetrazine or adrenaline was given after a 4-h fast and a... PENICK S. B,HINKL...
Larsen, et al., " The Effect of Glucagon, Glucagon-(1-21)-Peptide, and Placebo on Duodenal Pressure Activity in Healthy Subjects, " Scand. J. Gastroenterol., 21:634 (1986).Larsen, et al., The Effect of Glucagon, Glucagon (1 21) Peptide, and Placebo on Duodenal Pressure Activity in ...
Incretins, such as glucagon-like peptide-1 (GLP)-1, have been shown to elevate plasma insulin concentration. The purpose of this study is to investigate the cellular and molecular basis of the beneficial effects of GLP-1. Normal and diabetic male Wistar rats were treated with GLP-1 (50 ng...
The effect of glucagon on gluconeogenesis was measured in periportal and pericentral regions of the liver lobule by monitoring changes in rates of O2 uptake on the surface of the perfused liver with miniature O2 electrodes after infusion of lactate. When lactate (2 mM) was infused into livers ...
A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans. J Clin Endocrinol Metab 2001; 86: 4382–4389. CAS PubMed Google Scholar Turton MD, O’Shea D, Gunn I, Beak SA, Edwards CM, Meeran K et al. A role for glucagon-like ...
this, some of the more promising pharmacological therapies also involve modulation of the GI tract. For example, glucagon-like peptide-1 (GLP-1) agonists and dipeptidyl peptidase-4 inhibitors used for T2D treatment originate from gut-derived signaling mechanisms5. Even metformin, the most prescribed...
Female Sprague Dawley rats given semi-synthetic diet to appetite until 37 days of age, in 2 groups of 6, were given for 7 days 1 mg glucagon per kg bodyweight subcutaneously twice daily, or saline for controls, and blood samples were taken on the 7th day. At 58 days of age the injec...
Lin SZ, Zhang TL (1989) Effect of glucagon on the motility of esophageal smooth muscle. Chin Med J 102:193–199 PubMed CAS Google Scholar Trenkner SW, Maglinte DD, Lehman GA, Chernish SM, Miller RE, Johnson SW (1983) Esophageal food impaction: treatment with glucagon. Radiology 149...